Mehta Vimal's Form 4 filing
BioXcel Therapeutics, Inc. (BTAIQ) · filed Apr 8, 2024
- Accession no.
- 0001104659-24-044861
- Filed
- Apr 8, 2024
- Trade date
- Mar 14-Apr 4, 2024
- Filing delay
- 25 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $13.8K. It was filed 25 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mehta VimalCIK 0001733369 | Director, Officer (CEO and President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 14, 2024 | Common Stock | MOption exerciseAcquired | +2,610 | – | – | 34,832 | Direct | |
| Mar 15, 2024 | Common Stock | MOption exerciseAcquired | +14,000 | – | – | 48,832 | Direct | |
| Apr 4, 2024 | Common Stock | SSaleDisposed | −829 | $2.62 | −$2,171.98 | 48,003 | Direct | |
| Apr 4, 2024 | Common Stock | SSaleDisposed | −4,439 | $2.62 | −$11,630.18 | 43,564 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 14, 2024 | Common Stock | MOption exerciseDisposed | −2,610 | $0.00 | $0 | 20,875 | Direct | |
| Mar 15, 2024 | Common Stock | MOption exerciseDisposed | −14,000 | $0.00 | $0 | 42,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.